Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Processa Pharmaceuticals Q3 2026 Results: Net Loss of $183M, Loss Widens

Processa Pharmaceuticals reported a significant net loss of $189.8 million for the nine months ended September 30, 2026, primarily driven by a $178.0 million charge for acquired in-process research and development following the acquisition of Vidya Therapeutics. The company significantly strengthened its liquidity position during the period, ending with $180.2 million in cash and cash equivalents following a $200.0 million private placement financing.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-183.2-3.4
EPS (diluted, $ a share)$-61.58$-1.81

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: PCSA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Processa Pharmaceuticals, Inc.: key numbers

Share price
$1.72Close, Nov 16
Market cap
$4.81M
Shares outstanding
2.8MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Processa Pharmaceuticals, Inc.

All →
8:10 AM ET 8-K
Business Update

Processa Pharmaceuticals Business Update

Processa Pharmaceuticals issued a stockholder letter outlining its strategic shift toward immunological and inflammatory (I&I) diseases following its July acquisition of Vidya Therapeutics. The company highlighted the advancement of its lead BTK inhibitor candidate, VT-7208, into Phase 2 development for food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis, supported by approximately $183.3 million in net cash proceeds.

8:11 AM ET 8-K
Executive Compensation

Processa Pharmaceuticals Executive Compensation

Processa Pharmaceuticals appointed Gregory J. Flesher as Chief Operating Officer, effective November 4, 2026. Mr. Flesher will receive an annual base salary of $700,000, a target bonus of up to 60%, and an initial stock option grant representing 3.0% of the company's fully-diluted capital stock, contingent on shareholder approval of a new equity incentive plan.

8:47 AM ET 8-K
Regulatory Approval

Processa Pharmaceuticals Regulatory Approval

Processa Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for VT-7208, allowing the company to initiate a Phase 2 study in patients with chronic spontaneous urticaria. The company also appointed Dr. Sheila Gujrathi as Executive Chair and entered into a research collaboration with Generian Pharmaceuticals to expand its pipeline.

7:21 AM ET 8-K/A
M&A Deal

Processa Pharmaceuticals M&A Deal with Vidya Therapeutics, Inc.

Processa Pharmaceuticals filed an amendment to its 8-K to provide audited financial statements and pro forma information following its acquisition of Vidya Therapeutics. The deal adds VT7208, a CNS-penetrant BTK inhibitor, to Processa's pipeline for the treatment of autoimmune conditions like multiple sclerosis and food allergies.

Counterparty
Vidya Therapeutics, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.